A Systematic Approach to the Diagnosis of Suspected Central Nervous System Lymphoma

Overview

Journal JAMA Neurol

Publisher American Medical Association

Date 2013 Jan 16

PMID 23319132

Citations 62

Authors

Brian J Scott

Vanja C Douglas

Tarik Tihan

James L Rubenstein

S Andrew Josephson

Affiliations

Soon will be listed here.

Abstract

Central nervous system (CNS) lymphoma can present a diagnostic challenge. Currently, there is no consensus regarding what presurgical evaluation is warranted or how to proceed when lesions are not surgically accessible. We conducted a review of the literature on CNS lymphoma diagnosis (1966 to October 2011) to determine whether a common diagnostic algorithm can be generated. We extracted data regarding the usefulness of brain and body imaging, serum and cerebrospinal fluid (CSF) studies, ophthalmologic examination, and tissue biopsy in the diagnosis of CNS lymphoma. Contrast enhancement on imaging is highly sensitive at the time of diagnosis: 98.9% in immunocompetent lymphoma and 96.1% in human immunodeficiency virus-related CNS lymphoma. The sensitivity of CSF cytology is low (2%-32%) but increases when combined with flow cytometry. Cerebrospinal fluid lactate dehydrogenase isozyme 5, β2-microglobulin, and immunoglobulin heavy chain rearrangement studies have improved sensitivity over CSF cytology (58%-85%) but have only moderate specificity (85%). New techniques of proteomics and microRNA analysis have more than 95% specificity in the diagnosis of CNS lymphoma. Positive CSF cytology, vitreous biopsy, or brain/leptomeningeal biopsy remain the current standard for diagnosis. A combined stepwise systematic approach outlined here may facilitate an expeditious, comprehensive presurgical evaluation for cases of suspected CNS lymphoma.

Citing Articles

Tissue Is the Issue: The Diagnosis of Butterfly Brain Lesions.

Valerio J, Santiago Rea N, Zumaeta J, Graham B, Mantilla-Farfan P, Sanchez R Cureus. 2025; 16(12):e75538.

PMID: 39803131 PMC: 11722003. DOI: 10.7759/cureus.75538.

Unveiling the Clinical and Imaging Signatures of Intravascular Lymphoma of the Central Nervous System: A Multicentric Cohort Study.

Berthet E, Guillonnet A, Houillier C, Ursu R, Soussain C, Touat M Ann Neurol. 2024; 97(3):435-448.

PMID: 39605186 PMC: 11831878. DOI: 10.1002/ana.27132.

A Report of a Rare Case of a Solitary Ring-Enhancing Lesion in a Patient With Positive Toxoplasma Serology.

Chernicki B, Cobo Dominguez B, Huzior M, Caushi J, Aguirre C, Chokshi R Cureus. 2024; 16(10):e72062.

PMID: 39569225 PMC: 11578621. DOI: 10.7759/cureus.72062.

Prognostic Impacts of Age, Diagnosis Time, and Relapses in Primary CNS Lymphoma.

Ohanyan S, Buxbaum C, Stein P, Ringelstein-Harlev S, Shelly S J Clin Med. 2024; 13(16).

PMID: 39200887 PMC: 11355736. DOI: 10.3390/jcm13164745.

A 79-Year-Old Woman With Worsening Headaches and Pachymeningeal Enhancement: A Case Report From the National Multiple Sclerosis Society Case Conference Proceedings.

Sheth M, Hale D, McArthur J, Zamvil S, Goldman M, Riley C Neurol Neuroimmunol Neuroinflamm. 2024; 11(6):e200308.

PMID: 39190855 PMC: 11357841. DOI: 10.1212/NXI.0000000000200308.

References

Thurnher M, Rieger A, Settinek U, Henk C, Haberler C, Schindler E . Primary central nervous system lymphoma in AIDS: a wider spectrum of CT and MRI findings. Neuroradiology. 2001; 43(1):29-35. DOI: 10.1007/s002340000480. View

Lawrie C . MicroRNAs and haematology: small molecules, big function. Br J Haematol. 2007; 137(6):503-12. DOI: 10.1111/j.1365-2141.2007.06611.x. View

Lossos I, Breuer R, Intrator O, Lossos A . Cerebrospinal fluid lactate dehydrogenase isoenzyme analysis for the diagnosis of central nervous system involvement in hematooncologic patients. Cancer. 2000; 88(7):1599-604. View

Zaki H, Jenkinson M, Du Plessis D, Smith T, Rainov N . Vanishing contrast enhancement in malignant glioma after corticosteroid treatment. Acta Neurochir (Wien). 2004; 146(8):841-5. DOI: 10.1007/s00701-004-0282-8. View

ONeill B, DINAPOLI R, Kurtin P, Habermann T . Occult systemic non-Hodgkin's lymphoma (NHL) in patients initially diagnosed as primary central nervous system lymphoma (PCNSL): how much staging is enough?. J Neurooncol. 1995; 25(1):67-71. DOI: 10.1007/BF01054724. View

Balmaceda C, Gaynor J, Sun M, Gluck J, DeAngelis L . Leptomeningeal tumor in primary central nervous system lymphoma: recognition, significance, and implications. Ann Neurol. 1995; 38(2):202-9. DOI: 10.1002/ana.410380212. View

Hayakawa T, Takakura K, Abe H, Yoshimoto T, Tanaka R, Sugita K . Primary central nervous system lymphoma in Japan--a retrospective, co-operative study by CNS-Lymphoma Study Group in Japan. J Neurooncol. 1994; 19(3):197-215. DOI: 10.1007/BF01053274. View

Cavaliere R, Petroni G, Lopes M, Schiff D . Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer. 2010; 116(4):863-70. PMC: 4113953. DOI: 10.1002/cncr.24834. View

Johnson B, Fram E, Johnson P, JACOBOWITZ R . The variable MR appearance of primary lymphoma of the central nervous system: comparison with histopathologic features. AJNR Am J Neuroradiol. 1997; 18(3):563-72. PMC: 8338430. View

10.

Quijano S, Lopez A, Sancho J, Panizo C, Deben G, Castilla C . Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J Clin Oncol. 2009; 27(9):1462-9. DOI: 10.1200/JCO.2008.17.7089. View

11.

Buhring U, Herrlinger U, Krings T, Thiex R, Weller M, Kuker W . MRI features of primary central nervous system lymphomas at presentation. Neurology. 2001; 57(3):393-6. DOI: 10.1212/wnl.57.3.393. View

12.

Hunt M, Jahnke K, Murillo T, Neuwelt E . Distinguishing primary central nervous system lymphoma from other central nervous system diseases: a neurosurgical perspective on diagnostic dilemmas and approaches. Neurosurg Focus. 2006; 21(5):E3. DOI: 10.3171/foc.2006.21.5.4. View

13.

Mavlight G, Stuckey S, Cabanillas F, Keating M, Tourtellotte W, Schold S . Diagnosis of leukemia or lymphoma in the central nervous system by beta 2-microglobulin determination. N Engl J Med. 1980; 303(13):718-22. DOI: 10.1056/NEJM198009253031302. View

14.

Nelson D, Martz K, Bonner H, Nelson J, NEWALL J, KERMAN H . Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 1992; 23(1):9-17. DOI: 10.1016/0360-3016(92)90538-s. View

15.

Baumgartner J, Rachlin J, Beckstead J, Meeker T, Levy R, Wara W . Primary central nervous system lymphomas: natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome. J Neurosurg. 1990; 73(2):206-11. DOI: 10.3171/jns.1990.73.2.0206. View

16.

Di Noto R, Scalia G, Abate G, Gorrese M, Pascariello C, Raia M . Critical role of multidimensional flow cytometry in detecting occult leptomeningeal disease in newly diagnosed aggressive B-cell lymphomas. Leuk Res. 2008; 32(8):1196-9. DOI: 10.1016/j.leukres.2007.12.016. View

17.

Hoster E, Dreyling M, Klapper W, Gisselbrecht C, Van Hoof A, Kluin-Nelemans H . A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2007; 111(2):558-65. DOI: 10.1182/blood-2007-06-095331. View

18.

Ferreri A . How I treat primary CNS lymphoma. Blood. 2011; 118(3):510-22. DOI: 10.1182/blood-2011-03-321349. View

19.

Abrey L, Batchelor T, Ferreri A, Gospodarowicz M, Pulczynski E, Zucca E . Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005; 23(22):5034-43. DOI: 10.1200/JCO.2005.13.524. View

20.

Cinque P, Brytting M, Vago L, Castagna A, Parravicini C, Zanchetta N . Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system. Lancet. 1993; 342(8868):398-401. DOI: 10.1016/0140-6736(93)92814-a. View